Health & Biotech Dimerix awarded $2.8 million R&D tax incentive claim to advance ACTION3 Phase 3 trial February 17, 2023 Special Report: Dimerix will gain early access to forecast FY23 R&D Tax Incentive (RDTI), strengthening its financial position to continue… ASX Health Stocks: CleanSpace and Sonic Healthcare leap double digits today on US, trial wins February 16, 2023 Respiratory protection equipment maker CleanSpace (ASX: CSX) has secured a national sales agency contract for the US industrial market. Wellnex Life completes first delivery of Pharmacy Own products to leading pharmacy distributor CH2 February 14, 2023 Special Report: Wellnex Life will gain immediate national distribution for its Pharmacy Own products through a joint venture with Australia’s… ASX Health Stocks: Clarity Pharma shows effectiveness in diagnosing prostate lesions in Phase 1 trial February 14, 2023 Clarity Pharma reports success in Phase 1 study Antisense gets approval in Turkey Radiopharm to list on Nasdaq Capital Market… ASX Health Stocks: Emyria surges another 10pc; cannabis play Vitura delivers record profit February 13, 2023 Emyria (ASX:EMD) says it has secured sufficient clinical-grade MDMA to support its MDMA-assisted therapy for over 70 patients. ScoPo’s Powerplays: ASX health stocks fall but cap raises show money flowing into sector February 10, 2023 ASX health stocks have fallen this week with Healius dropping 15% in the past five days as H1 FY23 results… PharmAust reports extension of survival time and quality of life from MPL trial for dogs with B-cell lymphoma February 10, 2023 Special Report: PharmAust has set up veterinary trial centres in Australia, New Zealand and the United States to evaluate the… CardieX Raises $4.5 million as it gears up for dual US listing as CONNEQT Pulse awaits FDA Clearance February 10, 2023 Special Report: Australian Medtech CardieX has completed a $4.5million placement, continuing the company’s progress in positioning itself for a potential… Dimerix ticks another box in its Action3 Phase-3 FSGS kidney trial February 10, 2023 Special Report: Dimerix has announced another milestone for its pivotal Phase-3 trial with a positive report on a key review… ASX Health Stocks: Argenica rockets by 30pc after showing potential breakthrough on Alzheimer’s February 9, 2023 Argenica Therapeutics (ASX:AGN) has today shown that its lead drug, ARG-007, significantly inhibited one of the main causes of Alzheimers. Next» « Previous